Epinoma GTM brain

Epinoma develops methylation-preserving DNA amplification technology for epigenetics research, diagnostics and biopharma partnerships.

category

Epigenetics research and diagnostic technology

market profile

  • text: Epigenetic marks can inform disease detection and drug development, but current measurement methods may degrade or convert DNA.
  • text: Epinoma positions EpiAmp for methylation analysis while also describing longer-term epigenetic therapeutics ambitions.

personas

  • title: Biopharma translational research director
    pains:
    • Identifying meaningful epigenetic differences between healthy and diseased samples
    • Selecting preclinical compounds and patient populations with limited biomarker insight
  • title: Molecular diagnostics assay development lead
    pains:
    • Preserving methylation information while amplifying scarce DNA
    • Validating robust methods for circulating tumor DNA analysis
  • title: Epigenomics research scientist
    pains:
    • Noisy or degrading conversion-based methods
    • Studying methylation patterns with limited biological material

icp

  • text: Biopharma R&D groups developing drugs or biomarker-driven patient stratification; firm size is not specified.
  • text: Diagnostics developers and research labs studying methylation and circulating tumor DNA, particularly oncology.

message pillars

  • text: Preserve epigenetic information during amplification.
  • text: Expose useful gene expression information through epigenetic marks.
  • text: Support research toward better patient selection.

objections

  • objection: Is this method validated for our sample and use case?
    response: Request analytical performance data and evaluate a representative sample set before adopting it.
  • objection: Will the technology work with our existing assay and sequencing workflow?
    response: Discuss protocol compatibility, sample requirements and technology transfer with the team.
  • objection: Can this be used clinically today?
    response: Confirm intended use, evidence and regulatory status directly; the website describes development rather than a cleared clinical test.

competitors

  • name: Epigenica
    why: Develops epigenetic screening tools for research applications.
  • name: Chroma Medicine
    why: Adjacent epigenetic medicines company, competing for therapeutic partnerships rather than identical assays.
  • name: FOXO Technologies
    why: Works on epigenetic biomarkers and diagnostics.

keywords

  • methylation preserving DNA amplification
  • epigenetic biomarker discovery
  • DNA methylation assay development
  • liquid biopsy methylation
  • circulating tumor DNA methylation
  • epigenetic drug discovery

voice

  • Scientific and exploratory
  • Ambitious and partnership-oriented

signals

  • text: A biopharma team is building methylation-based biomarkers or patient stratification into a development program.
  • text: A diagnostics lab is developing a circulating tumor DNA assay and needs methylation analysis.

stack

  • Benchling
  • SnapGene
  • NCBI BLAST
  • Primer3

hiring

  • Technology Development Scientist
  • Diagnostic Development Research Associate

pricing

model: unknown

motion

sales_led

channels

  • partnerships
  • LinkedIn

confidence

medium

Founders

  • name: Varun Govil
    title: Founder
    role: Founder
    bio: Background in translational medicine with previous biotech and medtech development experience. Passionate about developing technologies that will change patients' lives.
  • name: Zhijian Li
    title: Founder
    role: Founder
    bio: Background in chemistry and biomedical science. In depth experience in developing novel methods for diagnosis and prognosis. Passionate about improving patient outcome with innovative sciences and technologies.

Back to YC companies